Get the Stockscreener App
231.47
6.93%
14.98
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $231.47, with a volume of 4.54M.
It is up +6.93% in the last 24 hours and up +7.32% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$216.49
Open:
$221.94
24h Volume:
4.54M
Relative Volume:
0.71
Market Cap:
$409.36B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
114.17
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+4.47%
1M Performance:
+7.32%
6M Performance:
+1.57%
1Y Performance:
+24.92%
1-Day Range:
$221.94
$232.32
1-Week Range:
$215.37
$232.32
52-Week Range:
$181.73
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, NVS, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
231.69 | 382.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,107.97 | 979.64B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.88 | 549.78B | 96.36B | 21.04B | 17.80B | 8.6488 |
NVS
Novartis Ag Adr
|
148.97 | 280.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
MRK
Merck Co Inc
|
114.98 | 281.24B | 65.51B | 8.93B | 14.12B | 3.5532 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-26 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Truist reiterates Kymera stock Buy rating after AbbVie deal By Investing.com - Investing.com Canada
Crude Oil Falls Over 2%; Getty Images Shares Spike Higher - Benzinga
Take care of migraines with headache-free advice from AbbVie - WSBT
AbbVie gains as investors weigh stronger growth outlook and recent pipeline wins - Quiver Quantitative
AbbVie Inc. (ABBV) Announces Acquisition of Apogee Therapeutics - GuruFocus
AbbVie sharpens immunology focus with $10.9 billion Apogee deal - reuters.com
ABBV Acquires Apogee Therapeutics for $10.9 Billion to Boost Imm - GuruFocus
AbbVie Acquires Apogee Therapeutics for $10.9 Billion to Expand Immunology Pipeline - GuruFocus
ABBV: Acquisition adds high-value immunology assets with blockbuster potential and early 2030 launch - TradingView
AbbVie deepens immunology legacy in $10.9bn Apogee buyout - Pharmaceutical Technology
Apogee Therapeutics (NASDAQ:APGE) stock jumps on AbbVie’s $10.9 billion cash takeover - TechStock²
RCSIntnl. BiotechnologyPortfolio company Apogee to be acquired by AbbVie - TradingView
AbbVie to buy Waltham’s Apogee Therapeutics in nearly $11 billion deal - The Boston Globe
AbbVie on Pace for Largest Percent Increase Since October 2025 -- Data Talk - Moomoo
AbbVie (ABBV) Set to Acquire Apogee Therapeutics (APGE) for $11 Billion - GuruFocus
AbbVie acquires Apogee Therapeutics in $10.9B deal - grafa.com
AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Deal - marketscreener.com
AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead? - Yahoo Finance
AbbVie Inc Stock (ABBV) Opened Up by 3.26% on Jun 22: Key Drivers Unveiled - TradingKey
AbbVie To Acquire Immunology Drug Maker Apogee For $10.9 Bln Cash; Shares Climb - RTTNews
Paul Weiss, Kirkland Steer $10.9B AbbVie, Apogee Deal - Law360
AbbVie seals $10.9B deal to acquire Waltham biotech Apogee Therapeutics - The Business Journals
AbbVie to buy immunology drugmaker Apogee for close to $11B - Crain's Chicago Business
As AbbVie eyes Apogee, these biotech stocks earn the highest Quant ratings (IBB:NASDAQ) - Seeking Alpha
AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs - BioPharma Dive
AbbVie (ABBV) Set to Acquire Apogee Therapeutics for $10.9 Billi - GuruFocus
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition - Benzinga
AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion - WSJ
AbbVie (ABBV) Acquires Apogee Therapeutics, Impact on Regeneron Analyzed - GuruFocus
AbbVie Strikes $10.9 Billion Deal for Apogee to Strengthen Future Immunology Portfolio (ABBV) - Yahoo Finance
Apogee Therapeutics, BitFuFu rise premarket; AbbVie gains after deal By Investing.com - Investing.com Canada
AbbVie’s $10.9 Billion Apogee Therapeutics Buyout Protects Its Immunology Crown - Barron's
AbbVie (ABBV) to Acquire Apogee Therapeutics (APGE) for $10.9 Bi - GuruFocus
AbbVie (ABBV) to Acquire Apogee Therapeutics for $10.9 Billion - GuruFocus
AbbVie bets US$10.9 billion on Apogee in next-generation immunology growth push - BNN Bloomberg
Abbvie To Acquire Apogee Therapeutics, Deepening Immunology Portfolio - TradingView
Apogee Acquisition Ticks AbbVie’s I&I Boxes - Citeline News & Insights
AbbVie to buy Apogee Therapeutics in nearly $11B deal - statnews.com
AbbVie To Buy Apogee Therapeutics For $10.9 Billion - Pulse 2.0
AbbVie to acquire Apogee Therapeutics (NASDAQ: APGE) in $10.9B cash deal - Stock Titan
AbbVie strikes $10.9B deal for Apogee Therapeutics - Axios
AbbVie (ABBV) Announces $10.9B Acquisition of Apogee Therapeutics - GuruFocus
AbbVie (ABBV) Pursues Apogee Therapeutics for Strategic Acquisition - GuruFocus
Form 8K AbbVie Inc For: 22 June By Investing.com - Investing.com Canada
AbbVie to acquire Apogee Therapeutics for $10.9 billion By Investing.com - Investing.com Canada
Global Market Update: AbbVie’s $10.9B Acquisition, Nasdaq-100 Rebalance Spark Overnight Volatility - stl.news
AbbVie to Acquire Apogee Therapeutics for $10.9B, Adds late‑stage IL‑13 asset Zumilokibart - TradingView
AbbVie strikes $10.9 billion deal for Apogee Therapeutics - Yahoo Finance
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio - Yahoo Finance
Wells Fargo Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $260 - Moomoo
5 Dividend Stocks to Buy and Hold Forever - The Motley Fool
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):